Trial Profile
UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 07 Oct 2021 Planned primary completion date changed from 30 May 2021 to 30 May 2022.
- 19 Apr 2021 Planned End Date changed from 3 Mar 2021 to 30 May 2022.
- 19 Apr 2021 Planned primary completion date changed from 3 Mar 2021 to 30 May 2021.